Karuna Therapeutics, Inc. hopes to raise at least $600m on the back of better-than-expected Phase III efficacy data for its novel therapy for schizophrenia that have set the product on a path to a US regulatory filing mid-next year.
The M1/M4-preferring muscarinic receptor agonist candidate, KarXT (xanomeline-trospium), has achieved positive results in a second Phase III trial, EMERGENT-2, meeting...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)